NorthWest Biotherapeutics Inc (NWBO)

[ATLnsider]

Yes, that is what I believe.

But, I believe the analogy should be “2 grand slams”, because of the magnitude of the advancement DCVax-L will provide in treating ndGBM and rGBM patients (in terms of a significant increase in overall survival (OS) and significantly increasing the percentage of patients who are effectively cured (5+ years of complete remission) (DCVax-L alone will effectively cure upwards of 30% to 35% percent of DCVax-L treated patients) (probably an even higher percentage if you include future patients who will be treated with DCVax-L combined with Keytruda, and will also be effectively cured).